ライフサイエンスコーパス: mirtazapine

1 eased by the antidepressants desipramine and mirtazapine.

2 n), (3) 1 mg/kg mirtazapine, or (4) 5 mg/ kg mirtazapine.

3 rence 1.17, 95% CI -0.23 to 2.58; p=0.10) or mirtazapine (0.01, -1.37 to 1.38; p=0.99), or between pa

4 In the telemetry model, mirtazapine (0.3-3 mg/kg, i.p.) caused an increase in TS

5 Administration of mirtazapine (1-3 mg/kg, i.p.) resulted in a slight decre

6 ndent model of thermoregulatory dysfunction, mirtazapine (10 mg/kg, i.p.) induced an increase in tail

7 Pretreatment with mirtazapine 24h prior to the CPP test had no effect on C

8 Random assignment to daily oral mirtazapine (30 mg) or placebo; both arms included 30-mi

9 for venlafaxine, 210.3 mg (SD=95.2); and for mirtazapine, 35.7 mg (SD=17.6).

10 ive sertraline (target dose 150 mg per day), mirtazapine (45 mg), or placebo (control group), all wit

11 To determine if mirtazapine altered the expression of MSn, on day 11, ra

12 This study reports the effects of mirtazapine, an antidepressant with 5-HT(1) agonist as w

13 QIDS-SR(16) response rates were 13.4% for mirtazapine and 16.5% for nortriptyline.

14 reated with the serotonin reuptake inhibitor mirtazapine and remains neurologically stable, with reso

15 .38; p=0.99), or between participants in the mirtazapine and sertraline groups (1.16, -0.25 to 2.57;

16 ) and atypical antidepressants (agomelatine, mirtazapine), and significant negative affective biases

17 maceuticals (efavirenz (EFV), acetaminophen, mirtazapine, and galantamine) prescribed for indications

18 ecently introduced: venlafaxine, nefazodone, mirtazapine, and reboxetine.

19 from 73% (22 of 30) to 44% (12 of 27) in the mirtazapine arm.

20 With respect to saline injections, mirtazapine at all three doses reduced apnea index durin

21 In contrast, a 30min pretreatment of mirtazapine attenuated the expression of both CPP and MS

22 tidepressants (eg, nefazodone hydrochloride, mirtazapine, bupropion hydrochloride, and venlafaxine hy

23 ovariectomized (OVX) rats has suggested that mirtazapine can alleviate thermoregulatory dysfunction b

24 significantly more among participants taking mirtazapine compared with those taking placebo (number o

25 st commonly prescribed drugs, sertraline and mirtazapine, compared with placebo.

26 Mirtazapine did not have significant efficacy on post-my

27 Mirtazapine, escitalopram, venlafaxine, and sertraline w

28 Mirtazapine exhibited potent functional antagonism (EC(5

29 , on day 11, rats received a pretreatment of mirtazapine, followed 30min later by a challenge injecti

30 ertraline group (46 of 107, 43%; p=0.010) or mirtazapine group (44 of 108, 41%; p=0.031), and fewer s

31 p=0.023), but not in a combined venlafaxine-mirtazapine group (n=140; accuracy 51.4%, p=0.53), sugge

32 treat analysis, participants assigned to the mirtazapine group had fewer methamphetamine-positive uri

33 ine group and 13.7% for the venlafaxine plus mirtazapine group).

34 up and the extended-release venlafaxine plus mirtazapine group, and the rates were not statistically

35 cific (5-HT1) serotonergic transmission, and mirtazapine has therefore been termed a noradrenergic an

36 atment with extended-release venlafaxine and mirtazapine in patients with treatment-resistant major d

37 ake inhibitors, nefazodone, venlafaxine, and mirtazapine) in participants younger than 19 years with

38 at the highest dose tested (10 mg/kg, i.p.), mirtazapine induced a small but significant decrease in

39 ting improved NREM sleep consolidation after mirtazapine injection.

40 Mirtazapine is a potent antagonist of central 2alpha-adr

41 Mirtazapine is an atypical antidepressant receiving atte

42 at functional blockade of these receptors by mirtazapine is not a likely mechanism for restoring ther

43 injection of: (1) saline, (2) 0.1 mg/kg +/- mirtazapine (labeled as Remeron), (3) 1 mg/kg mirtazapin

44 Collectively, these results indicate that mirtazapine may help to maintain abstinence in opioid de

45 Antidepressant therapy with 15 to 45 mg/d of mirtazapine (n = 124) or 20 to 40 mg/d of paroxetine (n

46 (N=58) or extended-release venlafaxine plus mirtazapine (N=51).

47 cific (non-SSRI) antidepressants (bupropion, mirtazapine, nefazodone, and venlafaxine), tricyclic ant

48 etine, escitalopram, fluoxetine, imipramine, mirtazapine, nefazodone, nortriptyline, paroxetine, sert

49 italopram oxalate, fluoxetine hydrochloride, mirtazapine, nortriptyline hydrochloride, paroxetine hyd

50 ive serotonin reuptake inhibitor [SSRI]) and mirtazapine (not an SSRI) in 246 elderly patients with m

51 esent study were to reexamine the effects of mirtazapine on temperature regulation in OVX rat models

52 irtazapine (labeled as Remeron), (3) 1 mg/kg mirtazapine, or (4) 5 mg/ kg mirtazapine.

53 We conclude that mirtazapine, over a 50-fold dose range, significantly re

54 of NREM sleep was unaffected by any dose of mirtazapine (p = 0.42), but NREM EEG delta power was inc

55 opram, fluoxetine, fluvoxamine, milnacipran, mirtazapine, paroxetine, reboxetine, sertraline, and ven

56 as tested on day 10 following a 24h or 30min mirtazapine pretreatment.

57 For mirtazapine, remission rates were 12.3% and 8.0% per the

58 To examine this finding further, mirtazapine's effect on CBT was determined.

59 We propose that mirtazapine should be investigated further for use in PM

60 ast, HTR2A 102 T/C genotype had no effect on mirtazapine side effects.

61 rictions, and ease of use of venlafaxine and mirtazapine suggest that this combination may be preferr

62 urrent investigation assessed the ability of mirtazapine to ameliorate morphine-induced behaviors.

63 present study evaluated the effectiveness of mirtazapine to reduce both behaviors.

64 The addition of mirtazapine to substance use counseling decreased metham

65 study compared the efficacy of switching to mirtazapine to that of switching to a tricyclic antidepr

66 Results from mirtazapine-treated patients indicate that the effect of

67 Among mirtazapine-treated patients, there was little indicatio

68 Surprisingly, among mirtazapine-treated subjects, S allele carriers had fewe

69 domly assigned to 14 weeks of treatment with mirtazapine (up to 60 mg/day) (N=114) or nortriptyline (